Pivoting from conflicting and controversial press over the company’s approved Alzheimer’s disease treatment, Biogen announced that its gene therapy drug timrepigene emparvovec failed to show a clinically meaningful benefit for a rare inherited eye disease in a Phase III trial.
Novartis cut three Phase III trials of the eye therapy Beovu (brolucizumab) after the studies showed higher rates of intraocular inflammation with frequent dosing intervals of the therapy.
AbCellera and Kodiak Sciences announced a new partnership to create and develop therapeutic antibodies for ophthalmologic indications.
Harbour BioMed closed a $102 million Series C funding round that will be used to advance the company’s oncology and immunology portfolio.
Baltimore-based AsclepiX Therapeutics closed a $35 million Series A financing.
Swiss drugmakers Roche and Novartis underscored how their portfolios are increasingly clashing on the commercial battlefield, announcing new data on drugs aimed at capturing market share from each other.
Paris-based GenSight Biologics reported the first group of data from Week 96 of the company’s RESCUE Phase III clinical trial.
Gyroscope Therapeutics – with headquarters in Stevenage, UK – is merging with Ambler, Pennsylvania-based Orbit Biomedical. The companies will operate under the Gyroscope name and focus on gene therapies for diseases of the eye.
Regeneron Pharmaceuticals is investing $800 million in Alnylam Pharmaceuticals to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference technology.
Scores of clinics across the United States directly advertise expensive – but unproven – cell therapy procedures to patients with serious eye diseases, often with devastating results, a new study warns.